Yi-Hao Hsu
Overview
Explore the profile of Yi-Hao Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
46
Followers
0
Related Specialties
Related Specialties
Co-Authors
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chiang I, Chen S, Hsu Y, Shahidi F, Yen G
Eur J Pharmacol
. 2024 Feb;
967:176393.
PMID: 38325792
Sunitinib (SUN) is the first-line targeted therapeutic drug for advanced renal cell carcinoma (RCC). However, SUN resistance is frequently observed to result in tumor metastasis, with a poor survival rate....
2.
Hong C, Chen S, Hsu Y, Yen G
Food Res Int
. 2022 Jun;
157:111390.
PMID: 35761646
Dysbiosis of gut microbiota is intimately related to ulcerative colitis. The literature has revealed the gut microbiota metabolism of dietary fiber, which is a key resource for short-chain fatty acids...
3.
Chen S, Hsu Y, Wang S, Chen Y, Hong C, Yen G
Phytother Res
. 2022 Feb;
36(4):1664-1677.
PMID: 35224793
Gemcitabine (GEM) drug resistance remains a difficult challenge in pancreatic ductal adenocarcinoma (PDAC) treatment. Therefore, identifying a safe and effective treatment strategy for PDAC is urgent. Lucidone is a natural...
4.
Wang G, Chen S, Chen Y, Hong C, Hsu Y, Yen G
Phytomedicine
. 2020 Oct;
80:153382.
PMID: 33113506
Background: Although gastroprotective drugs have been used for peptic ulcer disease prevention and treatment, side effects have been observed. Finding a safe and effective treatment strategy is important. Purpose: Edible...
5.
Hsu Y, Chen S, Wang S, Lin J, Yen G
Biomolecules
. 2020 May;
10(5).
PMID: 32375296
Gemcitabine (GEM) drug resistance causes high mortality rates and poor outcomes in pancreatic ductal adenocarcinoma (PDAC) patients. Receptor for advanced glycation end products (RAGE) involvement in the GEM resistance process...